METHODS OF DETECTING CANCER WITH ANTIBODIES TO CYTOKINE RECEPTOR ZCYTOR19
First Claim
1. A method for detecting a cancer in a patient, comprising:
- obtaining a tissue or biological sample from a patient;
incubating the tissue or biological sample with an antibody that specifically binds to the polypeptide of;
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 223 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 226 (Asn);
(c) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 249 (Trp);
(d) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 250 (Lys) to amino acid number 491 (Arg);
(e) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 250 (Lys) to 520 (Arg);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 491 (Arg);
(g) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 21 (Arg) to amino acid number 520 (Arg);
(h) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 1 (Met) to amino acid number 491 (Arg);
(i) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 1 (Met) to amino acid number 520 (Arg);
(j) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 21 (Arg) to amino acid number 163 (Trp);
(k) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 21 (Arg) to amino acid number 211 (Ser); and
(l) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 1 (Met) to amino acid number 211 (Ser);
under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample;
visualizing the antibody bound in the tissue or biological sample; and
comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
-
Citations
1 Claim
-
1. A method for detecting a cancer in a patient, comprising:
-
obtaining a tissue or biological sample from a patient;
incubating the tissue or biological sample with an antibody that specifically binds to the polypeptide of;
(a) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 223 (Pro);
(b) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 226 (Asn);
(c) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 249 (Trp);
(d) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 250 (Lys) to amino acid number 491 (Arg);
(e) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 250 (Lys) to 520 (Arg);
(f) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 21 (Arg) to amino acid number 491 (Arg);
(g) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 21 (Arg) to amino acid number 520 (Arg);
(h) the amino acid sequence as shown in SEQ ID NO;
2 from amino acid number 1 (Met) to amino acid number 491 (Arg);
(i) the amino acid sequence as shown in SEQ ID NO;
19 from amino acid number 1 (Met) to amino acid number 520 (Arg);
(j) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 21 (Arg) to amino acid number 163 (Trp);
(k) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 21 (Arg) to amino acid number 211 (Ser); and
(l) the amino acid sequence as shown in SEQ ID NO;
21 from amino acid number 1 (Met) to amino acid number 211 (Ser);
under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample;
visualizing the antibody bound in the tissue or biological sample; and
comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.
-
Specification